These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3838347)

  • 1. Low-dose 131I in treatment of Graves' disease.
    Lowdell CP; Dobbs HJ; Spathis GS; McCready VR; Cosgrove DO; Harmer CL
    J R Soc Med; 1985 Mar; 78(3):197-202. PubMed ID: 3838347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 125I therapy in Graves' disease. Long-term results in 355 patients.
    McDougall IR; Greig WR
    Ann Intern Med; 1976 Dec; 85(6):720-3. PubMed ID: 1036667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
    Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
    Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
    Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
    Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
    Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
    J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose radioiodine given six-monthly in Graves' disease.
    Hoskin PJ; Spathis GS; McCready VR; Cosgrove DO; Harmer CL
    J R Soc Med; 1985 Nov; 78(11):893-8. PubMed ID: 3840844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome following standardized 185 MBq dose 131I therapy for Graves' disease.
    Watson AB; Brownlie BE; Frampton CM; Turner JG; Rogers TG
    Clin Endocrinol (Oxf); 1988 May; 28(5):487-96. PubMed ID: 3214941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
    Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
    Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
    Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
    Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compensated low-dose 131I therapy of Graves' disease.
    Roudebush CP; Hoye KE; DeGroot LJ
    Ann Intern Med; 1977 Oct; 87(4):441-3. PubMed ID: 578665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.
    Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK
    J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism.
    Marcocci C; Gianchecchi D; Masini I; Golia F; Ceccarelli C; Bracci E; Fenzi GF; Pinchera A
    J Endocrinol Invest; 1990 Jun; 13(6):513-20. PubMed ID: 2258580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graves' disease and atrial fibrillation: the case for even higher doses of therapeutic iodine-131.
    Scott GR; Forfar JC; Toft AD
    Br Med J (Clin Res Ed); 1984 Aug; 289(6442):399-400. PubMed ID: 6432116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.